Ingredient or product comparison
GHK-Cu Cosmetic Wrinkle Reduction Complete Guide 2026: Mechanism Comparison
The table below compares GHK-Cu to other established anti-aging actives by mechanism, clinical evidence, and adverse event profile. GHK-Cu 0.05% TGF-beta receptor agonist + MMP-2/MMP-9 modulation 14–27% depth reduction in 8–12 weeks <5% (mild erythema) First-l
This source-based comparison does not add ratings or recommend a winner.
- The table below compares GHK-Cu to other established anti-aging actives by mechanism, clinical evidence, and adverse event profile.
- GHK-Cu 0.05%
- TGF-beta receptor agonist + MMP-2/MMP-9 modulation
- 14–27% depth reduction in 8–12 weeks
- <5% (mild erythema)
- First-line for retinoid-intolerant patients; minimal irritation with comparable collagen synthesis to low-dose tretinoin
- Tretinoin 0.05%
- Retinoic acid receptor binding → collagen-I gene upregulation
- 16–30% depth reduction in 12 weeks
- 35–50% (peeling, photosensitivity)
- Gold standard for wrinkle reduction; requires sunscreen compliance and tolerance titration
- Matrixyl (palmitoyl pentapeptide-4)
- TGF-beta signalling via different receptor subset
- 8–12% depth reduction in 12 weeks
- <2% (transient redness)
- Lower efficacy ceiling than GHK-Cu; suitable for mild photoaging only
- Vitamin C (L-ascorbic acid 15%)
- Cofactor for prolyl hydroxylase in collagen synthesis
- 10–15% depth reduction in 16 weeks
- 12–18% (oxidative irritation at pH <3.5)
- Requires pH <3.5 for stability. Often incompatible with GHK-Cu in same formulation
- Niacinamide 5%
- Ceramide synthesis + pigmentation reduction
- 6–9% depth reduction in 12 weeks
- <3% (flushing in rosacea patients)
- Primarily barrier-repair and tone correction; minimal structural collagen effect